Characterised by an excessive fear of social and performance situations where the individual is afraid of being embarrassed or negatively evaluated by others.
One of the most common and impairing mental disorders with a high risk for comorbid anxiety, depressive, and substance-use/abuse-related disorders.
Assessment is based on self-reporting, clinical interview, and behavioural observation.
Selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and cognitive behavioural therapy are considered the first-line treatments.
Long-term clinical management and monitoring are typically required, as patients are prone to relapse following discontinuation of acute treatment.
The condition involves an excessive fear of social or performance situations. The individual will often fear being embarrassed, or worry about being negatively evaluated by others. Anticipatory anxiety and situational avoidance are common, and the individual may endure social situations with a high level of discomfort. The scope of the anxiety may be focused on specific types of social situations or generalised to almost any social encounter.
History and exam
Craig N. Sawchuk, PhD
Department of Psychiatry and Psychology
CNS declares that he has no competing interests.
Jason P. Veitengruber, MD
Department of Psychiatry and Behavioral Sciences
University of Washington School of Medicine
JPV declares that he has no competing interests.
Bunmi O. Olatunji, PhD
Department of Psychological Sciences
BOO declares that he has no competing interests.
Stacy Shaw Welch, PhD
Anxiety and Stress Reduction Center of Seattle
University of Washington
SSW declares that she has no competing interests.
Richard P. Swinson, MD, FRCPC, FRCPsych
Anxiety Treatment and Research Centre
McMaster University and St Joseph’s Hospital
RPS declares that he has no competing interests.
Jeffrey M. Lohr, PhD
Department of Psychology
University of Arkansas
JML declares that he has no competing interests.
David F. Tolin, PhD
Institute of Living
DFT declares that he has no competing interests.
David Baldwin, MD
Professor of Psychiatry
University of Southampton
DB has acted as a consultant for and held research grants from Cephalon, Eli Lilly, GSK, Lundbeck, Organon, Pfizer, Pharmacia, Roche, and Wyeth and has also acted as a consultant to Asahi, AstraZeneca, Grunenthal, Pierre Fabre, Servier, Sumitomo, and Wyeth. He has accepted paid speaking engagements in industry-supported satellite symposia and is co-author of the BAP evidence-based guidelines on the treatment of anxiety disorders. He is also a Medical Patron of Anxiety UK.
- More guidelines
Use of this content is subject to our disclaimer